Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Achromatopsia: early-phase trial registry
1 of 4 indexed Achromatopsia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Achromatopsia: 4 US clinical trials tracked, 1 recruiting.
Achromatopsia is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Beacon Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition achromatopsia
OPEN 1 | RECR 25% | LATE 0 | EARLY 2 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Achromatopsia lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Achromatopsia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Achromatopsia is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Inherited Retinal Degenerative Disease Registry
Foundation Fighting Blindness
NCT02435940
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
Beacon Therapeutics
NCT02599922
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
Beacon Therapeutics
NCT02935517
Clinical and Genetic Characterization of Individuals With Achromatopsia
Beacon Therapeutics
NCT01846052
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Achromatopsia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Achromatopsia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Achromatopsia page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Achromatopsia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Beacon Therapeutics sponsors the most Achromatopsia trials on record, review their full trial history before evaluating a specific study. See Beacon Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Achromatopsia condition card totals 4 registered trials; most-linked intervention AGTC-402; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.